Stemline Therapeutics in-licensed the exclusive worldwide rights to SL-401, a Phase I compound directed at a cancer stem cell target from the Scott & White Cancer Research Institute/Texas A&M Health Science Center College of Medicine. SL-401 has reportedly demonstrated single agent antitumor activity in a multicenter, dose-escalation study.
SL-401 targets the interleukin-3 receptor (IL-3R) and has been shown to impair the ability of cancer stem cells to form tumors. IL-3R is over-expressed on multiple hematological cancers. In AML, IL-3R is over-expressed on both leukemia blasts as well as leukemia cancer stem cells.